A screen for congenital abnormalities of the fetus done on the mother's blood serum during pregnancy to look for fetal trisomy, including Down syndrome. The original test comprised measurements of (1) serum alpha fetoprotein (decreased in the trisomies), (2) serum hCG (increased in trisomy 21, decreased in trisomy 18), and (3) serum estriol (decreased in trisomy 21, increased in trisomy 18). Note that only 60% of pregnancies with Down syndrome will be revealed by a triple test. Refinements have taken place, with 'free beta' (part of the hCG molecule) replacing hCG itself, and with the addition of PAPP-A replacing estriol, increasing the sensitivity and specificity of the test. Further gains in sensitivity and specificity comes from adding an ultrasound test for nuchal translucency. Even so, false positive tests are possible, which will be resolved only by performing CVS or amniocentesis, and so also are false negative tests, which means that CVS and amniocentesis should still be considered in otherwise high-risk situations.

A form of albumin (a protein in the blood) produced only by the fetus, but crosses the placenta and so is detectable in the mother's blood (measured with a serum alpha fetoprotein, as well as being usefully measured in amniotic fluid obtained by amniocentesis. Detectable in higher than usual concentration with certain open abnormalities involving the fetus's brain and spinal cord (namely anencephaly and spina bifida). Present in lower than usual concentration when there is a trisomyin the fetus, such as Down syndrome (or trisomy 21), trisomy 18 or possibly Klinefelter syndrome -- screening for all of which can be done with a triple test.

'Pregnancy-associated plasma protein A': a protein made by the syncytiotrophoblast of the placenta to increase its sensitivity to grow. Found in increasing levels in the pregnant woman's serum as pregnancy develops. Decreased if the pregnancy is affected by Down syndrome, therefore measured in the triple test used for fetal trisomy 21 screening.